People: ZIOPHARM Oncology Inc (ZIOP.O)

ZIOP.O on Consolidated Issue listed on NASDAQ Capital Market

4.86USD
26 Dec 2014
Price Change (% chg)

$0.09 (+2.00%)
Prev Close
$4.76
Open
$4.75
Day's High
$4.98
Day's Low
$4.70
Volume
188,356
Avg. Vol
1,011,314
52-wk High
$5.58
52-wk Low
$2.31

Search Stocks

Fowler, Wyche 

Brief Biography

Senator Wyche Fowler, Jr., J.D., is an Independent Director of ZIOPHARM Oncology, Inc. Previously served as a Director of ZIOPHARM, Inc. since December 2004. Senator Fowler served for 16 years in the United States Congress. In the U.S. Senate he served as assistant floor leader, helping mold a bipartisan consensus for public policy issues. Senator Fowler was a member of the U.S. Senate Appropriations, Budget, Energy and Agriculture Committees. First elected to the U.S. House of Representatives, he was a member of the Ways and Means and Foreign Affairs Committees, as well as the Select Committee on Intelligence. President Clinton appointed Senator Fowler U.S. Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. On his return, the FBI awarded him its highest civilian honor, The Jefferson Cup, for his assistance in combating terrorism and for helping solve terrorism crimes against the U.S. military in Saudi Arabia. He was named Lion of Judah by the State of Israel for freeing Soviet Jew Yakov Gluzman. Senator Fowler is now engaged in an international business and law practice, and also serves as Chairman of the Board of the Middle East Institute, a non-profit foundation in Washington, DC. Senator Fowler also serves on the board of directors of Shubert Theaters, the Shubert Foundation, Brandywine Realty Trust and Keryx Biopharmaceuticals, Inc., a biopharmaceutical company. Senator Fowler holds an A.B. in English from Davidson College and a J.D. from Emory University School of Law.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Jonathan Lewis

1,692,670

Kevin Lafond

347,763

Caesar Belbel

912,418

Murray Brennan

--

Randal Kirk

--

James Cannon

--
As Of 30 Dec 2013
Search Stocks